다른 서비스와 비교했을 때 VRTX 의 PS 비율은 어느 정도인가요?

VRTX은 Price-To-Sales 비율(10.9x)을 기준으로 볼 때 동종 업체의 평균(4.9x)과 비교했을 때 비쌉니다.

VRTX 의 PS 비율은 US Biotechs 업계의 다른 회사와 어떻게 비교됩니까?

VRTX 은 US Biotechs 과 비교하여 Price-To-Sales 비율( 10.9 x)을 기준으로 비용이 많이 듭니다. Biotechs 업계 평균( 10.1 x).

VRTX 의 PS 비율과 공정 PS 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PS 비율입니다.

VRTX 10.9 예상 공정 Price-To-Sales Price-To-Sales 비율 8.8 x).

미래 현금 흐름을 볼 때 VRTX 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

VRTX ( $451.23 )는 당사 추정치인 [[공정 가치]]( $859.38 )

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

목표주가는 현재 주가 대비 20 % 미만입니다.

Vertex Pharmaceuticals (Nasdaq:VRTX) - 주가, 뉴스 및 분석

VRTX 주식 개요

생명공학 회사인 버텍스 파마슈티컬스는 낭포성 섬유증(CF) 치료를 위한 치료법을 개발하고 상용화하는 일을 하고 있습니다. 자세한 내용

VRTX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	4/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 47.5% 에서 거래

수익은 매년 47.38% 증가할 것으로 예상됩니다.

위험 분석

위험 검사에서 VRTX 에 대한 위험이 감지되지 않았습니다.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Expanding Horizons In Biotech With Groundbreaking Therapies And Growth Opportunities

Key Takeaways Expanding patient access and new product launches drive revenue growth in cystic fibrosis and highlight significant revenue potential. Advancements in transformative therapies like VX-880 and global expansions offer substantial opportunities for revenue diversification and growth.

View narrative

US$513.87

12.2% undervalued

8.75%

Revenue growth p.a.

Updated

Vertex Pharmaceuticals Incorporated 경쟁사

Gilead Sciences

NasdaqGS:GILD

US$109.2b

Amgen

NasdaqGS:AMGN

US$150.5b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$80.1b

AbbVie

NYSE:ABBV

US$294.4b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Vertex Pharmaceuticals
과거 주가
현재 주가	US$451.23
52주 최고치	US$519.88
52주 최저치	US$346.29
베타	0.39
11개월 변경	-5.62%
3개월 변경 사항	-5.97%
1년 변경 사항	27.74%
33년 변화	142.28%
5년 변화	105.05%
IPO 이후 변화	9,927.33%

최근 뉴스 및 업데이트

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Recent updates

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03

주주 수익률

	VRTX	US Biotechs	US 마켓
7D	-8.8%	-6.5%	-1.0%
1Y	27.7%	14.6%	30.3%

수익률 대 산업: VRTX 지난 1년 동안 14.6 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: VRTX 지난 1년 동안 30.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is VRTX's price volatile compared to industry and market?
VRTX volatility
VRTX Average Weekly Movement	3.9%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: VRTX 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: VRTX 의 주간 변동성( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1989	5,400	Reshma Kewalramani	www.vrtx.com

생명공학 회사인 버텍스 파마슈티컬스는 낭포성 섬유증(CF) 치료제를 개발 및 상용화하는 데 주력하고 있습니다. F508del 변이가 하나 이상 있는 2세 이상의 CF 환자를 위한 트리카프타/카프트리오, 6세 이상의 CF 환자를 위한 심데코/심메비, 1년 이상의 CF 환자를 위한 오캄비, 1년 이상의 CF 환자를 위한 칼리데코, 이바카프토를 판매하고 있습니다. 이 회사의 파이프라인에는 임상 1상 시험 중인 CF의 근본 원인을 치료하기 위해 고안된 CFTR mRNA 치료제인 VX-522, 임상 3상 시험 중인 급성 및 신경병증성 통증 치료를 위한 비오피오이드 의약품인 VX-548, 임상 2/3상 시험 중인 겸상 적혈구 질환 및 수혈 의존성 베타 지중해빈혈 치료를 위한 엑사셀이 포함됩니다.

Vertex Pharmaceuticals Incorporated 기본 사항 요약

Vertex Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
VRTX 기본 통계
시가총액	US$115.38b
수익(TTM)	-US$479.80m
수익(TTM)	US$10.63b

10.9x

P/S 비율

-242.2x

P/E 비율

VRTX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
VRTX 손익 계산서(TTM)
수익	US$10.63b
수익 비용	US$4.93b
총 이익	US$5.69b
기타 비용	US$6.17b
수익	-US$479.80m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.86
총 마진	53.59%
순이익 마진	-4.52%
부채/자본 비율	0%

VRTX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

VRTX 주식 개요

보상

위험 분석

Expanding Horizons In Biotech With Groundbreaking Therapies And Growth Opportunities

Vertex Pharmaceuticals Incorporated 경쟁사

NasdaqGS:GILD

US$109.2b

NasdaqGS:AMGN

US$150.5b

NasdaqGS:REGN

US$80.1b

NYSE:ABBV

US$294.4b

가격 내역 및 성능

최근 뉴스 및 업데이트

CEO, President & Director notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Recent updates

CEO, President & Director notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Executive VP & Chief Legal Officer notifies of intention to sell stock

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Executive Chairman notifies of intention to sell stock

Second quarter 2024 earnings: EPS misses analyst expectations

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

CEO, President & Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

CEO, President & Director notifies of intention to sell stock

Consensus EPS estimates fall by 12%

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

CEO, President & Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Executive VP & COO notifies of intention to sell stock

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Full year 2023 earnings: EPS exceeds analyst expectations

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Executive VP & CFO notifies of intention to sell stock